US2726982A - Hydrous gels - Google Patents

Hydrous gels Download PDF

Info

Publication number
US2726982A
US2726982A US164028A US16402850A US2726982A US 2726982 A US2726982 A US 2726982A US 164028 A US164028 A US 164028A US 16402850 A US16402850 A US 16402850A US 2726982 A US2726982 A US 2726982A
Authority
US
United States
Prior art keywords
gel
parts
hydrous
acetic acid
gels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US164028A
Inventor
Irving L Ochs
Preston L Veltman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US164028A priority Critical patent/US2726982A/en
Priority to GB11908/51A priority patent/GB696608A/en
Priority to FR1043022D priority patent/FR1043022A/en
Application granted granted Critical
Publication of US2726982A publication Critical patent/US2726982A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/02Compresses or poultices for effecting heating or cooling
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/00051Accessories for dressings
    • A61F13/00063Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0066Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/008Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001Body part
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/00157Wound bandages for burns or skin transplants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00519Plasters use for treating burn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00902Plasters containing means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21Acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents

Definitions

  • This invention relates to compositions of use in a number of fields and particularly to gels carrying or having incorporated therein an active ingredient whereby such gel may be used as a reservoir or depot for said active ingredient, and to methods of producing and of utilizing said gels.
  • a wet dressing also requires frequent attention and the required care is not always available. Because of the inherent porosity of a Wet dressing and the necessity for keeping the area accessible, contamination and secondary infection by air-borne organisms often occurs. Also, it is diflicult to keep a continuous liquid phase in contact with raw tissue. Or, considering the treatment of corneal ulcers, the use of solutions is disadvantageous in that it is impossible to immobilize the eye due to the necessity of frequently applying drops or solutions to maintain an effective concentration of medicament. In addition, the movement of the eye-lid over the ulcer is painful and healing is inhibited by mechanical irritation, thus slowing the process of epithelization. Further, in the treatment of body cavities or fistulae, whose location is such that they are drained by gravity, solutions can not be applied effectively.
  • hydrous gels containing an active ingredient which gel thus serves as a reservoir or depot supply for said active ingredient to a particular environment.
  • hydrous gels carrying a lower fatty acid such as acetic acid in effective concentrations for the utilization desired as for example in therapeutic amounts when used for therapeutic purposes.
  • a hydrous gel is used as a carrier for an active ingredient so that such hydrous gel carrying said ingredient may be piaced at the locality to which the active ingredients is to be supplied, and the gel will serve as a reservoir or depot supply for the active ingredient which is continuously supplied therefrom to the locality.
  • hydrous gels carrying active ingredients may be used effectively to maintain a source of supply of active ingredient without requiring constant attention.
  • the invention is particularly useful in therapeutic application and may well be illustrated by the use of hydrous gels carrying organic acids, such as acetic acid.
  • hydrous gels may be made from inorganic components such as of silica, alumina, ferric oxide, etc., or from organic components such as carboxymethyl cellulose and other carboxy alkyl celluloses, pectins, polyvinyl alcohol, gelatin, partially oxidized cellulose, agar, fibrin, albumin, starch, etc.
  • Such gels may be prepared by conventional methods and the active ingredient incorporated into them, either after production of the gel or preferably during its preparation.
  • water soluble active ingredients may be incorporated into the water or aqueous solution used in preparing the sol from which the gel is formed.
  • the gels used in accordance with the present invention are hydrous gels or hydrophilic gels since for therapeutic purposes, water transfer is an important desideratum. Further, it is a simple matter to prepare such gels with thixotropic properties by conventional methods so that upon shaking they may be reduced in viscosity sufiiciently for application as a fluid, but promptly-set up to a substantially rigid structure or shape.
  • the character of active ingredient may vary depending on the particular field of utilization for the product.
  • the invention will be illustrated by the use of aliphatic acids as the active ingredient. Many of the these acids exhibit a sufficient germicidal action for utilization for therapeutic purposes including lower monobasic (fatty) acids such as formic, acetic, propionic, butyric, and Valerie acids, hydroxy monobasic acids such as glycoiic and lactic acids, and polybasic acids such as malonic, succinic, oxalic, aconitic, and citric acids. All of these acids exhibitsubstantial bactericidal action but it should be kept in mind that various factors govern the activity exhibited, and some of the acids are more effective against one type of bacteria than against another.
  • acetic acid is'lesse'fiective against Staphylococcus aureus than against Psujdomonas aerug'inosa,"Eberzhlla typhosa, onEscherichz'a coli.
  • citric acid In general with-v monobasic acids, .the bactericidal -action decreases with molecular we'ig'ht anddntroduction o'fhydroxygroups renders them' from two. to twelve..times more effective. The undisasso 'ciated molecule. plays amajor role'so that activity is not'due merely to pH.
  • the amount. of active ingredient employed will .depend. on the utilization .to which :the product is put. When used forjtherapeutic purposes, the amount ofactive fingredientr'should be kept below that which will cause undesired -irritation at the point of application.
  • a therapeutic amount .of acetic. acid should be employed, i.. e. .an :amount which will exhibit the des'iredeffect. Ordinarily, this will .notbe more than 4 parts by weight per 100 parts of water in the hydrous gel, and usually will be much less as for example 1.25 parts per 100 parts of waterinthe hydrous gel. There is no particular lower limit since any proportions may be used, but. amounts to give desired effects will .usually be at.least.0.0l to Q25 partyper 100 parts of waterin the hydrous gel.
  • Theproportions of water to gel-forming component maybe anything to give .a gel ofthe type desired. .
  • the V gradation -from.sol to gel is a gradual one, and the gel maytake various degrees of rigidity depending on the componentsand their proportions.
  • Water transfer is an important characteristic of hydrogels, and the elastic organic hydrogels are superior to the inorganic hydrogels .inthat'the-forrner not only lose'water indry air, but the hydration process is reversible, whereas with the inor ganic gels it is not. In general, satisfactory results will be obtained with the organic hydrous gel produced with from.5 to. 30 parts of, gel forming material to 100 parts of water, all parts being by weight.
  • composition which .is in the form of a hydrous, s'ubstanti'allyimmobile gel containing a small, but eifectivequantity of acetic acid.
  • the acetic acid and water were mixed and the powdered pectin added with good agitation to avoid lumping.
  • the mass was then warmed as for example to ap-.
  • the polyvinyl'alcohol may be DuPont-s Elvanol 71-24.
  • the water and acetic-acid were mixed and the powdered polyvinyl alcohol added with eificient 'mixing to form a gelatinous mass.
  • the powdered polyvinyl alcohol added with eificient 'mixing to form a gelatinous mass.
  • the mass may be heated as' at about 206 F. for approximately 30 minutes. Upon heating, the viscosity maybe reduced and greater fluidity developed. Increasingthe polyvinyl alcohol content makes a firmer composition capable of absorbing greater quantities of body fluids without becoming undesirably mobile.
  • the gel may-be .made by dissolving :the cellulosematerial'in the water acid solution following the procedures of; other examples asset forth above.
  • the partially oxidized cellulose is oxycellulose of which theParkeDavis & Co. product was used.
  • Various gradesof carboxymethylcellulose may be used including low viscosity 25 to.50 cps., medium viscosity 400 to 600. cps., and high viscosity approximately2000 cps.,. all measured in 2% solution.
  • .Adjuvants of various types may :be includedfor example, ;lanolin,.mineral oil, anestheticsyperfumes; coloring matter or dyes, for any particular:purposes. .TA; small? but effectiveaamount .of preservatives 1 such. asi sodiumirbenzoate, phenol, or hydroxyquinoline may be include'dain the; product.
  • Acetic ,:acid-. solutions of various concentrations' may be-used in lieu-50f: glacial aceticiacid.
  • :zMiXlllli'GS of gel-forming components may be employed, and mix tures of active ingredients may be utilized.
  • the hydrous gels carrying acetic acid are particularly useful for therapeutic purposes. It is not necessary to immobilize the patient nor keep the part undergoing treatment, exposed.
  • the gel acts as a reservoir and continued source of therapeut c substance, by permitting diffusion of the active agent to the surface of the diseased tissue.
  • the gelatinous mass also serves to absorb and maintain any body exudate in a liquid state. This prevents crusting over of the wound and in addition reduces the chance of infection.
  • the reservoir action makes frequent attention to the infected area unnecessary.
  • the physical quality of softness makes the gelatinous mass nonirritating mechanically and there are no fixed or rigid elements in the gel structure to become enmeshed with the healing tissue.
  • compositions of this invention favor the absorption of body fluids and electrolytes and the outer surface of the gel may be covered with an impermeable membrane to keep sterility and also dynamic equilibrium with the body fluids. Fluid from burns may enter the gel and return to the body from the gel just as from a sponge.
  • the use of the compositions of the present invention eliminate or materially reduce the possibility of contamination by air-borne organisms while the gelatinous mass provides complete protection for the wound by eliminating air pockets and unprotected areas.
  • the compositions of the present invention may desirably be used.
  • compositions described herein may be enclosed in surgical wounds of infected or contaminated areas and may subsequently be absorbed by the body tissues.
  • the adhesive nature of the materials of this invention permit them to adhere strongly to tissue surfaces even when the lotter are wet and consequently these compositions may be used effectively in body cavities and fistulae regardless of gravity effects.
  • Compositions of this invention when transparent are particularly useful in permitting a visual check of the healing process without disturbing the Wound or the therapeutic agent.
  • compositions of this invention may be used by treating any infected or potentially infected body tissues.
  • potentially infected tissue is meant areas Whose epithelium which normally protects the body against bacterial invasion is disrupted by heat, cold, or physical injury.
  • Compositions of this invention have been successfully used in treating a Wide variety of diseased tissue due to bacteriacidal action and they also promote healing by maintaining a sterile and epithelization promotion medium at the surface of the Wound.
  • compositions are particularly effective against gram negative bacilli. Burns of varying degree of severity can be successfully treated for optimum results. A primary burn of a mild type requires medication for safe healing and the treating composition may be selected to provide a gelatinous covering that will retain its therapeutic power in accordance with the amount of exudate issuing from the wound. One skilled in treatment may estimate with accuracy the amount of body fluid to be expected and the best suited and balanced composition applied accordingly. When the amount of exudate is small, a composition containing a minimum concentration of acetic acid may be used in the hydrous gel containing only a small reserve capacity before becoming undesirably mobile.
  • compositions of the present invention have been particularly successful in treating infections of the outer ear.
  • the adhesive is ideal in that the material remains in position even in the upper parts which it is quite impossible to treat with prior art fluid medicaments.
  • the potent bactericidal action of the sustained low concentration of acetic acid provided by the compositions of this invention have notably been successful in applications of this character. Numerous low order of infections of the hands, feet and scalp yield to treatment by compositions disclosed herein.
  • a topical therapeutic immobile hydrous gel to promote healing by controlling infection without injuring tissue consisting essentially of Water parts, gel forming material from 5 to 30 parts, and acetic acid, the acid being not over 4 parts, all parts being by weight, said gel forming material being selected from the group consisting of carboxymethyl cellulose, pectin powder, polyvinyl alcohol, gelatin and partially oxidized cellulose.
  • a topical therapeutic immobile hydrous gel to promote healing by controlling infection without injuring tissue consisting essentially of water 100 parts, gel forming material from 5 to 30 parts, and acetic acid, the acid being not over 4 parts, all parts being by weight, said gel forming material being a carboxyalkylcellulose.

Description

United States Patent HYDROUS GELS Irving L. Ochs, Annapolis, and Preston L. Veltman, Severna Park, Md.
No Drawing. Application May 24, 1950, Serial No. 164,028
7 Claims. Cl. 167-58) This invention relates to compositions of use in a number of fields and particularly to gels carrying or having incorporated therein an active ingredient whereby such gel may be used as a reservoir or depot for said active ingredient, and to methods of producing and of utilizing said gels.
It is frequently desirable or necessary to maintain a concentration of an active ingredient in a particular locality or environment in order to secure a specific action which is caused or enhanced by such active ingredient. An example is in the use of acetic acid solutions in wet dressing for the treatment of skin infections, as for example in the treatment of burns and of infected wounds. Such wet dressing technique has not been satisfactory due to its many limitations, and also because often it is impracticable for a given situation. It is known that surfaces denuded of epithelium vary greatly in the amount of fluid exuded. To maintain the optimal concentration of acetic acid at the surface of the wound requires adjust ment of the concentration of the acid in accordance with the degree of dilution of the exudate.
Wet dressings require that the part of the body, be ing treated be unclothed and immobilized. Further the solution requires replenishment at frequent intervals. This is troublesome and impractical with an 'ambulant patient. In addition, gauze carrying the solution for a wet dressing is irritating to the raw area to which it is applied due to its abrasive or other physical action. Furthermore, the healing wound often grows through the interstices of the gauze and when removed necessarily traumatizes the area being treated with consequent regression in the healing process. The gauze also acts as a wick favoring the evaporation of solution supplied by capillarity and body fluids, which in turn, results in a concentration of electrolytes which may act as irritants because of the resulting change in osmotic balance. Nor is there certainty of control over the concentration of medicament, when, of necessity, the area must be kept open with'consequent solution (water) evaporation.
A wet dressing also requires frequent attention and the required care is not always available. Because of the inherent porosity of a Wet dressing and the necessity for keeping the area accessible, contamination and secondary infection by air-borne organisms often occurs. Also, it is diflicult to keep a continuous liquid phase in contact with raw tissue. Or, considering the treatment of corneal ulcers, the use of solutions is disadvantageous in that it is impossible to immobilize the eye due to the necessity of frequently applying drops or solutions to maintain an effective concentration of medicament. In addition, the movement of the eye-lid over the ulcer is painful and healing is inhibited by mechanical irritation, thus slowing the process of epithelization. Further, in the treatment of body cavities or fistulae, whose location is such that they are drained by gravity, solutions can not be applied effectively.
"Besides therapeutic utilizations, there are many other situations in which it is desired to maintain a source of supply of a given reagent or reactant, or of an acid or base to maintain given conditions of acidity or pH. Intermittent or continuous introduction of solutions offers a number of the same difficulties referred to above in the use of wet dressings.
Among the objects of the present invention is the production of hydrous gels containing an active ingredient which gel thus serves as a reservoir or depot supply for said active ingredient to a particular environment. I
Further objects include such hydrous gels carrying a lower fatty acid such as acetic acid in effective concentrations for the utilization desired as for example in therapeutic amounts when used for therapeutic purposes.
Other objects include methods of producing such gels and their utilization.
Still further objects and advantages of the present invention will appear from the more detailed description set forth below, it being understood that such more detailed description is given by way of illustration and explanation only, and not by way of limitation, since various changes therein may be made by those skilled in the art without departing from the scope and spirit of the present invention.
In accordance with the present invention, a hydrous gel is used as a carrier for an active ingredient so that such hydrous gel carrying said ingredient may be piaced at the locality to which the active ingredients is to be supplied, and the gel will serve as a reservoir or depot supply for the active ingredient which is continuously supplied therefrom to the locality. Whether used therapeutically, or in chemical or physical processes, such hydrous gels carrying active ingredients may be used effectively to maintain a source of supply of active ingredient without requiring constant attention. The invention is particularly useful in therapeutic application and may well be illustrated by the use of hydrous gels carrying organic acids, such as acetic acid.
Various types of gels may be employed including both organic and inorganic gels. Thus hydrous gels may be made from inorganic components such as of silica, alumina, ferric oxide, etc., or from organic components such as carboxymethyl cellulose and other carboxy alkyl celluloses, pectins, polyvinyl alcohol, gelatin, partially oxidized cellulose, agar, fibrin, albumin, starch, etc. Such gels may be prepared by conventional methods and the active ingredient incorporated into them, either after production of the gel or preferably during its preparation. Thus water soluble active ingredients may be incorporated into the water or aqueous solution used in preparing the sol from which the gel is formed. Desirably the gels used in accordance with the present invention are hydrous gels or hydrophilic gels since for therapeutic purposes, water transfer is an important desideratum. Further, it is a simple matter to prepare such gels with thixotropic properties by conventional methods so that upon shaking they may be reduced in viscosity sufiiciently for application as a fluid, but promptly-set up to a substantially rigid structure or shape.
The character of active ingredient may vary depending on the particular field of utilization for the product. The invention will be illustrated by the use of aliphatic acids as the active ingredient. Many of the these acids exhibit a sufficient germicidal action for utilization for therapeutic purposes including lower monobasic (fatty) acids such as formic, acetic, propionic, butyric, and Valerie acids, hydroxy monobasic acids such as glycoiic and lactic acids, and polybasic acids such as malonic, succinic, oxalic, aconitic, and citric acids. All of these acids exhibitsubstantial bactericidal action but it should be kept in mind that various factors govern the activity exhibited, and some of the acids are more effective against one type of bacteria than against another. For example, acetic acid is'lesse'fiective against Staphylococcus aureus than against Psujdomonas aerug'inosa,"Eberzhlla typhosa, onEscherichz'a coli. The same is true of citric acid. In general with-v monobasic acids, .the bactericidal -action decreases with molecular we'ig'ht anddntroduction o'fhydroxygroups renders them' from two. to twelve..times more effective. The undisasso 'ciated molecule. plays amajor role'so that activity is not'due merely to pH.
However, for, present purposes, the waterrsolubility of the'acid -is anfimportant factor where use in a hydrous gel "is employed. .Moresoluble acids like acetic acid may desirably be utilized therefore and acetic acid will be referred to below in examplesillustrating the invention.
The amount. of active ingredient employed will .depend. on the utilization .to which :the product is put. When used forjtherapeutic purposes, the amount ofactive fingredientr'should be kept below that which will cause undesired -irritation at the point of application. Thus for hydrous. gels carrying aceticacid, used fortherapeutic purposes,.'a therapeutic amount .of acetic. acid should be employed, i.. e. .an :amount which will exhibit the des'iredeffect. Ordinarily, this will .notbe more than 4 parts by weight per 100 parts of water in the hydrous gel, and usually will be much less as for example 1.25 parts per 100 parts of waterinthe hydrous gel. There is no particular lower limit since any proportions may be used, but. amounts to give desired effects will .usually be at.least.0.0l to Q25 partyper 100 parts of waterin the hydrous gel.
.Simila'r amounts of the otheracids may be used. Nor .isit essentialthat all the acid present be in-solution.
"Theproportions of water to gel-forming component maybe anything to give .a gel ofthe type desired. .The V gradation -from.sol to gel is a gradual one, and the gel maytake various degrees of rigidity depending on the componentsand their proportions. Water transfer is an important characteristic of hydrogels, and the elastic organic hydrogels are superior to the inorganic hydrogels .inthat'the-forrner not only lose'water indry air, but the hydration process is reversible, whereas with the inor ganic gels it is not. In general, satisfactory results will be obtained with the organic hydrous gel produced with from.5 to. 30 parts of, gel forming material to 100 parts of water, all parts being by weight.
The following examples illustratev the invention parts being by weight unless otherwise indicated.
.This example illustrates a very desirable composition which .is in the form of a hydrous, s'ubstanti'allyimmobile gel containing a small, but eifectivequantity of acetic acid.
"Water 100 'iarboxymethyl -cellulose.. "20 -"Gla'cial=acetic-"acid I125 LI-he? .carboxymethyl cellulose -was .Hereules Type 7 0 and of low viscosity. .Theaceticacid and water were mixed and-the carboxymethyl cellulose added slowly with efiicient stirring to produce a smooth, uniform, gelatinous mass. It is desirable'toemploy vigorous-mixing toavoid lumpsand the product may be somewhat opaque due to occluded-air. The mass maybe heated to drive out the air,- as for example for 30 minutes at approximately 200 Water r Pectin powder l0 Glacial acetic acid 1.25
The acetic acid and water were mixed and the powdered pectin added with good agitation to avoid lumping. The mass was then warmed as for example to ap-.
proximately 200 F. for about 30 minutes to complete the hydration of the pectin. On cooling, a gelatinous mass was obtained which exhibited bactericidal prop'erties and promotes healing of. diseasedtissue. Variations in proportions as to pectin .and acetic acidmayb'e'madeias described aboveunder Example 1. Experience has shown that the above given composition is notably-efie'ctive in general use; however, where fluid exudation is copious, theacid concentration is optimally increased.
' III Water ,100 Polyvinyl alcohol 5 Glacial acetic acid 1.25
The polyvinyl'alcohol may be DuPont-s Elvanol 71-24. The water and acetic-acid were mixed and the powdered polyvinyl alcohol added with eificient 'mixing to form a gelatinous mass. To remove entrapped air, the
mass may be heated as' at about 206 F. for approximately 30 minutes. Upon heating, the viscosity maybe reduced and greater fluidity developed. Increasingthe polyvinyl alcohol content makes a firmer composition capable of absorbing greater quantities of body fluids without becoming undesirably mobile.
Water 100 Gelatin 10 Glacial acetic acid 1.25
The water and acetic acid were mixed, heated to about 200 F., and the powdered gelatin dissolved therein with efiicient stirring. The mass was cooled to a cleargelatinous .therapeutic composition. Proportions may be varied as setforth above butthe acidcontent most generally useful is. approximately 1.25.
Water "1'00 Partiallyoxidized. cellulose 10 Glacial acetic acid I125 lThe gel may-be .made by dissolving :the cellulosematerial'in the water acid solution following the procedures of; other examples asset forth above. The partially oxidized cellulose is oxycellulose of which theParkeDavis & Co. product was used.
Various gradesof carboxymethylcellulose may be used including low viscosity 25 to.50 cps., medium viscosity 400 to 600. cps., and high viscosity approximately2000 cps.,. all measured in 2% solution. Various grades of polyvinyl alcohols .may. be used including low viscosity 4 to -6 cps, medium viscosity20 to 28-cps., .and high viscosity 35 to. cps., allmeasured in- 4% :solution.
.Adjuvants of various types may :be includedfor example, ;lanolin,.mineral oil, anestheticsyperfumes; coloring matter or dyes, for any particular:purposes. .TA; small? but effectiveaamount .of preservatives 1 such. asi sodiumirbenzoate, phenol, or hydroxyquinoline may be include'dain the; product. Acetic ,:acid-. solutions of various concentrations'may be-used in lieu-50f: glacial aceticiacid. :zMiXlllli'GS of gel-forming components may be employed, and mix tures of active ingredients may be utilized.
The hydrous gels carrying acetic acid are particularly useful for therapeutic purposes. It is not necessary to immobilize the patient nor keep the part undergoing treatment, exposed. The gel acts as a reservoir and continued source of therapeut c substance, by permitting diffusion of the active agent to the surface of the diseased tissue. The gelatinous mass also serves to absorb and maintain any body exudate in a liquid state. This prevents crusting over of the wound and in addition reduces the chance of infection. The reservoir action makes frequent attention to the infected area unnecessary. The physical quality of softness makes the gelatinous mass nonirritating mechanically and there are no fixed or rigid elements in the gel structure to become enmeshed with the healing tissue. The compositions of this invention favor the absorption of body fluids and electrolytes and the outer surface of the gel may be covered with an impermeable membrane to keep sterility and also dynamic equilibrium with the body fluids. Fluid from burns may enter the gel and return to the body from the gel just as from a sponge. The use of the compositions of the present invention eliminate or materially reduce the possibility of contamination by air-borne organisms while the gelatinous mass provides complete protection for the wound by eliminating air pockets and unprotected areas. In applications Where a reservoir of therapeutic agent is desired along with immobilization of any part, the compositions of the present invention may desirably be used.
In specific applications, compositions described herein may be enclosed in surgical wounds of infected or contaminated areas and may subsequently be absorbed by the body tissues. The adhesive nature of the materials of this invention permit them to adhere strongly to tissue surfaces even when the lotter are wet and consequently these compositions may be used effectively in body cavities and fistulae regardless of gravity effects. Compositions of this invention when transparent are particularly useful in permitting a visual check of the healing process without disturbing the Wound or the therapeutic agent.
The compositions of this invention may be used by treating any infected or potentially infected body tissues. By potentially infected tissue is meant areas Whose epithelium which normally protects the body against bacterial invasion is disrupted by heat, cold, or physical injury. Compositions of this invention have been successfully used in treating a Wide variety of diseased tissue due to bacteriacidal action and they also promote healing by maintaining a sterile and epithelization promotion medium at the surface of the Wound.
These compositions are particularly effective against gram negative bacilli. Burns of varying degree of severity can be successfully treated for optimum results. A primary burn of a mild type requires medication for safe healing and the treating composition may be selected to provide a gelatinous covering that will retain its therapeutic power in accordance with the amount of exudate issuing from the wound. One skilled in treatment may estimate with accuracy the amount of body fluid to be expected and the best suited and balanced composition applied accordingly. When the amount of exudate is small, a composition containing a minimum concentration of acetic acid may be used in the hydrous gel containing only a small reserve capacity before becoming undesirably mobile. If the wound is severe and copious amounts of fluid are expected, a concentration containing acetic acid is desirably selected along with a hydrous gel specifically compounded to absorb large quantities of body fluids without becoming undesirably mobile. Thus the concentration of gelling agent should be proportioned to the amount of exudate. Compositions of the present invention have been particularly successful in treating infections of the outer ear. The adhesive is ideal in that the material remains in position even in the upper parts which it is quite impossible to treat with prior art fluid medicaments. The potent bactericidal action of the sustained low concentration of acetic acid provided by the compositions of this invention have notably been successful in applications of this character. Numerous low order of infections of the hands, feet and scalp yield to treatment by compositions disclosed herein.
Having thus set forth our invention, we claim:
1. A topical therapeutic immobile hydrous gel to promote healing by controlling infection without injuring tissue, consisting essentially of Water parts, gel forming material from 5 to 30 parts, and acetic acid, the acid being not over 4 parts, all parts being by weight, said gel forming material being selected from the group consisting of carboxymethyl cellulose, pectin powder, polyvinyl alcohol, gelatin and partially oxidized cellulose.
2. A topical therapeutic immobile hydrous gel to promote healing by controlling infection without injuring tissue, consisting essentially of water 100 parts, gel forming material from 5 to 30 parts, and acetic acid, the acid being not over 4 parts, all parts being by weight, said gel forming material being a carboxyalkylcellulose.
3. A topical therapeutic immobile hydrous gel as set forth in claim 1, said gel forming material being carboxymethyl cellulose.
4. A topical therapeutic immobile hydrous gel as set forth in claim 1, said gel forming material being pectin powder.
5. A topical therapeutic immobile hydrous gel as set forth in claim 1, said gel forming material being polyvinyl alcohol.
6. A topical therapeutic immobile hydrous gel as set forth in claim 1, said gel forming material being gelatin.
7. A topical therapeutic immobile hydrous gel as set forth in claim 1, said gel forming material being partially oxidized cellulose.
References Cited in the file of this patent UNITED STATES PATENTS Mattocks et al. Oct. 11, 1949 OTHER REFERENCES Loewe: American Journal Med. Sci., July 1944, pp. 54
Fantus et al.: Journal of the American Pharmaceutical Asso., vol. 28, No. 8, pp. 548 to 554.
Sulzberger et al.: Annals of Surgery, vol. 125, No. 4, April 1947, pp. 418 to 430.
Pharmaceutical Formulas, vol. I, p. 213, eleventh ed., The Chemist and Druggist, 1944.
Mattocks et al.: J. A. P. A. Scientific Ed., September 1946, pp. 275-279.
Dorrance et al.: Surgical Clinics of North America, 1922, pp. 299-303.
Connor et al.: Annals of Surgery, September 1944, pp. 362366.
Mantell: Water Soluble Gums, November 1947, Reinhold Pub. Corp., N. Y., p. 153.
J. A. M. A., vol. 133, No. 11, pp. 811-12, Mar. 15, 1947.

Claims (1)

1. A TOPICAL THERAPEUTIC IMMOBILE HYDROUS GEL TO PROMOTE HEALING BY CONTROLLING INFECTION WITHOUT INJURING TISSUE, CONSISTING ESSENTIALLY OF WATER 100 PARTS, GEL FORMING MATERIAL FROM 5 TO 30 PARTS, AND ACETIC ACID, THE ACID BEING NOT OVER 4 PARTS, ALL PARTS BEING BY WEIGHT, SAID GEL FORMING MATERIAL BEING SELECTED FROM THE GROUP CONSISTING OF CARBOXYMETHYL CELLULOSE, PECTIN POWDER, POLYVINYL ALCOHOL, GELATING AND PARTIALLY OXIDIZED CELLULOSE.
US164028A 1950-05-24 1950-05-24 Hydrous gels Expired - Lifetime US2726982A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US164028A US2726982A (en) 1950-05-24 1950-05-24 Hydrous gels
GB11908/51A GB696608A (en) 1950-05-24 1951-05-22 Hydrous gels for therapeutic purposes
FR1043022D FR1043022A (en) 1950-05-24 1951-05-24 Hydrogels, their preparation process and their applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US164028A US2726982A (en) 1950-05-24 1950-05-24 Hydrous gels

Publications (1)

Publication Number Publication Date
US2726982A true US2726982A (en) 1955-12-13

Family

ID=22592663

Family Applications (1)

Application Number Title Priority Date Filing Date
US164028A Expired - Lifetime US2726982A (en) 1950-05-24 1950-05-24 Hydrous gels

Country Status (3)

Country Link
US (1) US2726982A (en)
FR (1) FR1043022A (en)
GB (1) GB696608A (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025217A (en) * 1958-05-28 1962-03-13 Olin Mathieson Dry amylopectin therapeutic dusting powders
US3122481A (en) * 1956-08-07 1964-02-25 Ernest Norland Lipstick
US3234091A (en) * 1955-07-08 1966-02-08 Ciba Geigy Corp Shaped medicaments and process for their manufacture
US3432594A (en) * 1964-12-31 1969-03-11 Ciba Geigy Corp Coatings for rectal capsules and process for their manufacture
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4265875A (en) * 1976-07-23 1981-05-05 Inveresk Research International Controlled release suppositories
US4330531A (en) * 1976-03-26 1982-05-18 Howard Alliger Germ-killing materials
US4364929A (en) * 1979-04-02 1982-12-21 The Purdue Frederick Company Germicidal colloidal lubricating gels and method of producing the same
US4406883A (en) * 1976-07-23 1983-09-27 Merrell Dow Pharmaceuticals Inc. Controlled release suppositories consisting essentially of a linear polymer particularly, polyvinyl pyrrolidones
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
EP0162026A2 (en) * 1984-03-14 1985-11-21 Lic Care Aktiebolag A bacteria adsorbing composition
US4585797A (en) * 1981-04-13 1986-04-29 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4591501A (en) * 1981-04-13 1986-05-27 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4986990A (en) * 1984-03-21 1991-01-22 Alcide Corporation Disinfection method and composition therefor
US5100652A (en) * 1984-03-21 1992-03-31 Alcide Corporation Disinfecting oral hygiene compositions and process for using the same
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
US5618850A (en) * 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US6113629A (en) * 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
US20170002511A1 (en) * 2013-11-28 2017-01-05 Carl Freudenberg Kg Hydrogelling fibers and fiber structures

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342745A (en) * 1979-05-31 1982-08-03 Zyma S.A. Use of polyvinyl alcohols for the treatment of lesions
US5006557A (en) * 1990-04-19 1991-04-09 Siu Ming Yee Acne solution
DE69508356T2 (en) * 1994-12-08 1999-08-26 Kuraray Co Wound dressing
GB2322864A (en) * 1997-03-07 1998-09-09 Polybiomed Ltd Gel for application to the human or animal body
GB0424006D0 (en) * 2004-10-29 2004-12-01 Bluetrac Ltd A biological parallel contamination indicator
BR112013025956A2 (en) * 2011-04-12 2016-08-16 Unilever Nv oil-in-water emulsion and process for preparing an oil-in-water emulsion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2484637A (en) * 1946-08-20 1949-10-11 Southern Res Inst Powdered ointment base of methyl cellulose and sorbitol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2484637A (en) * 1946-08-20 1949-10-11 Southern Res Inst Powdered ointment base of methyl cellulose and sorbitol

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234091A (en) * 1955-07-08 1966-02-08 Ciba Geigy Corp Shaped medicaments and process for their manufacture
US3122481A (en) * 1956-08-07 1964-02-25 Ernest Norland Lipstick
US3025217A (en) * 1958-05-28 1962-03-13 Olin Mathieson Dry amylopectin therapeutic dusting powders
US3432594A (en) * 1964-12-31 1969-03-11 Ciba Geigy Corp Coatings for rectal capsules and process for their manufacture
US4330531A (en) * 1976-03-26 1982-05-18 Howard Alliger Germ-killing materials
US4292300A (en) * 1976-07-23 1981-09-29 Inveresk Research International Controlled release suppositories
US4265875A (en) * 1976-07-23 1981-05-05 Inveresk Research International Controlled release suppositories
US4406883A (en) * 1976-07-23 1983-09-27 Merrell Dow Pharmaceuticals Inc. Controlled release suppositories consisting essentially of a linear polymer particularly, polyvinyl pyrrolidones
US4364929A (en) * 1979-04-02 1982-12-21 The Purdue Frederick Company Germicidal colloidal lubricating gels and method of producing the same
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
US4591501A (en) * 1981-04-13 1986-05-27 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4585797A (en) * 1981-04-13 1986-04-29 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
EP0162026A2 (en) * 1984-03-14 1985-11-21 Lic Care Aktiebolag A bacteria adsorbing composition
EP0162026B1 (en) * 1984-03-14 1990-10-31 Lic Care Aktiebolag A bacteria adsorbing composition
US4986990A (en) * 1984-03-21 1991-01-22 Alcide Corporation Disinfection method and composition therefor
US5100652A (en) * 1984-03-21 1992-03-31 Alcide Corporation Disinfecting oral hygiene compositions and process for using the same
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
USRE36064E (en) * 1984-03-21 1999-01-26 Alcide Corporation Disinfection method and composition therefor
US5618850A (en) * 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5879688A (en) * 1995-03-09 1999-03-09 Focal, Inc. Hydroxy-acid cosmetics
US6261544B1 (en) 1995-03-09 2001-07-17 Focal, Inc. Poly(hydroxy acid)/polymer conjugates for skin applications
US6113629A (en) * 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
US20030100942A1 (en) * 1998-05-01 2003-05-29 Ken Christopher G. M. Hydrogel for the therapeutic treatment of aneurysms
US20170002511A1 (en) * 2013-11-28 2017-01-05 Carl Freudenberg Kg Hydrogelling fibers and fiber structures

Also Published As

Publication number Publication date
FR1043022A (en) 1953-11-05
GB696608A (en) 1953-09-02

Similar Documents

Publication Publication Date Title
US2726982A (en) Hydrous gels
US3761590A (en) Silver sulfadiazine used in the treatment of burns
DE69206407T3 (en) WOUND DRESSING.
US6251423B1 (en) Sterilizable paste product for topical application
CA2042609C (en) Wound gel compositions and method of using them
US3767784A (en) Composition for the protection and treatment of injured body tissue and method of utilizing the same
US2558395A (en) Undenatured gelatin hemostatic sponge containing thrombin
US5662924A (en) Wound dressing
CN103520764A (en) Functional dressing, and preparation method and application thereof
AU2014257984B2 (en) Composition for use in reducing scab formation and promoting healing
WO1990014110A1 (en) Improvements in or relating to pharmaceutical preparations
US20110171284A1 (en) Povidone-iodine and sucrose wound healing dressing
CN110859989B (en) Liquid band-aid and preparation method thereof
JPH05506861A (en) Compositions and methods for topical treatment of damaged or diseased tissue
HU200103B (en) Process for producing pharmaceutical compositions for treating lack of epithelium
US4232003A (en) Synthetic physiological mucus
JP2002104974A (en) Hydrogel therapeutic agent for damaged skin
JP3169621B2 (en) Antimicrobial external preparation
US2385262A (en) Therapeutic-anesthetic preparations
JPWO2007094413A1 (en) Pharmaceutical composition for transdermal administration
RU2568909C2 (en) Medical dressing, method for producing and using it
CN113440647A (en) Preparation method and application of ozone hydrogel dressing
Mohs Penicillin ointment-impregnated gauze in the local treatment of infections
CN113855850A (en) Dressing composition and preparation method and application thereof
Hallberg THE EXTERNAL PREPARATIONS AND THEIR THERAPY.